Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2/3 1Phase 1/2 1

Status

Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Myelodysplastic Syndromes 1Lymphoma 1Leukemia, Myeloid, Acute 1Leukemia, Biphenotypic, Acute 1Graft vs Host Disease 1

Interventions

Cisplatin 13Paclitaxel 11Cyclophosphamide 11Doxorubicin 10Magnetic Resonance Spectroscopy 9Gemcitabine 9Prednisone 8Docetaxel 8Specimen Handling 7Oxaliplatin 7Carboplatin 7Vincristine 6Etoposide 6Capecitabine 6pembrolizumab 5Rituximab 5Radiotherapy 5Leucovorin 5Cytarabine 5Bevacizumab 5atezolizumab 4Trastuzumab 4Platinum 4Nivolumab 4Fluorouracil 4Dexamethasone 4Biopsy 41,2-diaminocyclohexaneplatinum II citrate 4Watchful Waiting 3Taxes 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Active not recruiting × vedolizumab × Clear all
NCT06475820 2024-08-23

Preventing of GVHD With Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Baricitinib at Children and Young Adults With Hemoblastosis

Federal Research Institute of Pediatric Hematology, Oncology and Immunology

Phase 2/3 Active not recruiting
150 enrolled
LymphoidMyeloidOther hematologic neoplasm

Graft vs Host Disease, Lymphoma, Myelodysplastic Syndromes, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡